Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of tislelizumab plus pemetrexed in relapsed or refractory primary DLBCL of the CNS
KCT0007048Phase 2Active, not recruiting
- Sponsor
- BeiGene
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, pemetrexed in diffuse large B-cell lymphoma (DLBCL), sponsored by BeiGene. Started Aug 2022; status: active, not recruiting.
02
Drugs
tislelizumabpemetrexed
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on KCT0007048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007048.